

**CHOATE**

CHOATE HALL &amp; STEWART LLP

**RECEIVED  
CENTRAL FAX CENTER****MAR 07 2006****Fax****CONFIDENTIAL**

Recipient	Company	Fax	Phone
Art Unit 1653	USPTO	(571) 273-8300	


From	Nadège M. Lagneau, Ph.D.	Number of Pages	9 (including this page)
Date	March 7, 2006	Client Number	2004117-0008
Phone	(617) 248-5150	Operator	Time Sent

Comments	Applicant:	Carr, <i>et al.</i>	Examiner:	TBA
	Serial No.:	10/828,623	Group Art Unit:	1653
	Filed:	April 21, 2004		
	For:	NOVEL CHIMERIC ANALGESIC PEPTIDES		

Please find enclosed for filing in the above-identified patent application:

1. Transmittal (1 page);
2. PTO 1449 (1 page);
2. Supplemental IDS Statement (6 pages); and
3. Facsimile cover sheet (1 page).

Respectfully submitted,

  
Nadège M. Lagneau, Ph.D.  
Reg. No.: 51,908

Return by Inter-office Mail Hold for pick-up

This Message is transmitted to you by the law firm of Choate, Hall & Stewart LLP. The substance of this message, along with any attachments, may be confidential and legally privileged. If you are not the designated recipient of this message, please destroy it and notify the sender of the error by return e-mail or by calling 1-800-520-2427.

Under regulations of the Treasury Department, we are required to include the following statement in this message: Any advice contained herein (or in any attachment hereto) regarding federal tax matters was not intended or written by the sender to be used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

For more information about Choate, Hall & Stewart LLP, please visit us at [www.choate.com](http://www.choate.com)  
Two International Place | Boston MA 02110 | t 617-248-5000 | f 617-248-4000 | [choate.com](http://choate.com)

4051971v1


ATTORNEY DOCKET NUMBER: 2004117-0008 (NEMC 197-DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Carr, <i>et al.</i>	Examiner:	TBA
Serial No.:	10/828,623	Group Art Unit:	1653
Filed:	April 21, 2004		
For:	NOVEL CHIMERIC ANALGESIC PEPTIDES		

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Certificate of Facsimile Transmission	
Pursuant to 1096 OG 30-31	
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office (571) 273-8300 on the date indicated below.	
March 7, 2006	
Date	Signature
	Mary B. Wilson
Typed or Printed Name of person signing certificate	


TRANSMITTAL

Please find enclosed for filing in the above-identified patent application:

1. PTO 1449 (1 page);
2. Supplemental IDS Statement (6 pages); and
3. Facsimile cover sheet (1 page).

Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,



Nadège M. Lagneau, Ph.D.  
Reg. No.: 51,908

Dated: March 7, 2006

PATENT GROUP  
CHOATE, HALL & STEWART LLP  
Two International Place  
Boston, MA 02110  
Telephone: (617) 248-5000  
Facsimile: (617) 248-4000

<b>Form PTO-1449</b> <b>(REV. 8-83)</b>		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2004117-0008 (NEMC 197-DIV)		In re Application No. 10/828,623	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				Applicant: Carr <i>et al.</i>			
<i>(Use several sheets if necessary)</i>				Filing Date: April 21, 2004		Group: 1653	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass		
	✓ 6,063,758	Lappi <i>et al.</i>	05/16/00				
	✓ 6,310,072	Smith <i>et al.</i>	10/30/01				
<b>U. S. PATENT APPLICATIONS</b>							
	Document No.	Applicant	Filing Date				
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Document No.	Country	Publication Date	Translation			
				Yes	No		
Examiner's Initials	<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, <i>Etc.</i> )						
	✓ Cavagnero <i>et al.</i> , <i>Life Sci.</i> , 49(7):498-503, 1991.						
	✓ Watson <i>et al.</i> , <i>Eur. J. Pharmacol.</i> , 87(1):77-84, 1983.						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

✓ Cited by the Examiner in parent case USSN 09/428,692 (US Patent No.: 6,759,520).

RECEIVED  
CENTRAL FAX CENTER  
MAR 07 2006

ATTORNEY DOCKET NUMBER: 2004117-0008 (NEMC 197-DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Carr, <i>et al.</i>	Examiner:	TBA
Serial No.:	10/828,623	Group Art Unit:	1653
Filed:	April 21, 2004		
For:	NOVEL CHIMERIC ANALGESIC PEPTIDES		

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate of Facsimile Transmission	
Pursuant to 1096 OG 30-31	
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office (571) 273-8300 on the date indicated below.	
March 7, 2006	_____
Date	Signature
	Mary B. Wilson
Typed or Printed Name of person signing certificate	

Sir:

**STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☐ An *original* Information Disclosure Statement; or
- ☒ A *supplemental* Information Disclosure Statement.

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:

☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);

☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;

☒ Before the mailing of a first Office action on the merits; or

☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with a check mark ( ✓ ) is included;
- ☒ Copies of references indicated with a check mark ( ✓ ) on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously cited by the Examiner in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status
09/428,692	October 28, 1999	Granted
(Patent No.: 6,759,520)		

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☐ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:

[ ] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.



Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

  
Nadège M. Lagneau, Ph.D.  
Reg. No. 51,908

Dated: March 7, 2006

PATENT DEPARTMENT  
CHOATE, HALL & STEWART LLP  
Two International Place  
Boston, Massachusetts 02110  
Tel: (617) 248-5000  
Fax: (617) 248-4000